Sunvozertinib

舒沃替尼

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameSunvozertinib
Drug Alias NameSunvozertinib companion diagnosticSunvozertinib CDx舒沃哲ZEGFROVYDZD-9008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsEGFR L858R inhibitorsEGFR T790M inhibitors +[4] 
TargetsEGFR exon 20 insertion mutationsEGFR L858REGFR T790M +[4] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2023/08/22
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDizal (Jiangsu) Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDizal (Jiangsu) Pharmaceutical Co Ltd
Inactive CompaniesFudan UniversityDizal Pharmaceutical Co Ltd
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG